51 results about "Melatonin receptor agonist" patented technology

The invention relates to a method of treating diverse human disorders that may arise, in part, out of sleep hypoxia and oxygen deprivation occurring in the context of sleep apnea/hypopnea disturbances. The disorders that may be treated by the invention comprise gastroesophageal reflux disease (GERD), asthma-associated gastroesophageal reflux (GER), GER-associated asthma, asthma, cardiomyopathy, cardioarrhythmia, congestive heart failure, sudden infant death syndrome, and diverse neurologic conditions. The mode of treatment uses somatostatin receptor ligands (SstRLs), particularly somatostatin-receptor agonists. The invention concerns the method of treatment utilizing, and compositions comprising SstRLs and somatostatin receptor agonists, including agonists of the somatostatin receptor types 2 and 5, particularly, the type 2A receptor (SsR-2A), including octreotide and lanreotide.

This invention provides methods of administering (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclo-propyl]methyl]propanamide as a melatonin receptor agonist to a human subject to treat or prevent a circadian rhythm disorder or sleep disorder.

Agonists of the adenosine A2 receptor promote the migration of endothelial cells, fibroblasts and epithelial cells. Thus, methods and pharmaceutical compositions useful for treating wounds and promoting wound healing comprise agents which cause stimulation of the adenosine A2 receptor, preferably receptor agonists and adenosine uptake blockers. Preferred agonists include 2-phenylaminoadenosine, 2-para-2-carboxyethylphenyl-amino-5'N-ethylcarboxamidoadenosine, 5'N-ethylcarbox-amidoadenosine, 5'N-cyclo-propyladenosine, 5'N-methylcarboxamidoadenosine and PD-125944. Preferred uptake blockers include dipyridamole, nitrobenzylthio-inosine, dilazep and R75231.

This invention is directed to methods for preventing or ameliorating sleep-related breathing disorders. The method comprises administration to a patient in need thereof an effective dose of one or a combination of prostanoid receptor antagonists (eg. ramatroban, ifetroban, diphloretin, phosphate, polyphloretin phosphate, seratrodast, SC19220). The prostanoid receptor antagonist or combination of prostanoid receptor antagonists can be administered in conjunction with one or more serotonin receptor agonists, one or more cannabinoids receptor agonists, one or more serotonin reuptake inhibitors, one or more noradrenalin reuptake inhibitors, a combination of reuptake inhibitors, an inhibitor of prostanoid synthesis, or any combination of the foregoing.

Disclosed are A₃ adenosine receptor antagonists and/or partial agonists and A₁ adenosine receptor agonists and/or partial agonists of formula (I):

wherein R¹ to R⁵ are as described herein, as well as pharmaceutical compositions thereof and methods of use thereof. The A₃ AR antagonists or partial agonists find use in treating a number of diseases such as cancer, glaucoma, and inflammatory diseases, as well as in preventing cardiac ischemia. Also disclosed are radiolabeled compounds of formula (I) and the use thereof in diagnostic imaging of tissues and organs. The A₁ AR agonists and partial agonists find use in treating diseases such as seizures, convulsion, stroke, diabetes, pain, arrhythmias, depression, and anxiety and in cardioprotection or neuroprotection.

A medicament for the treatment of the phantom phenomena of acute tinnitus and/or phantom pain, a method for the production of such a medicament, and a method for the treatment of such phantom phenomena

A pharmaceutical composition or kit of parts comprising at least three ingredients from a HMG-CoA reductase inhibitor, a leukotriene antagonist, a proton pump inhibitor, melatonin or a melatonin receptor agonist, a bioavailable preparation of a curcuminoid, a calciferol derivative, a compound from the group consisting of metformin and phenformin, valproate, minocycline and chloroquine and one or more pharmaceutically acceptable carriers or excipients.

The invention provides an application of catechin (1) shown as a structural formula (I) or pharmaceutical thereof and a pharmaceutical composition thereof in preparing a melatonin receptor agonist, anapplication thereof in preparing medicines for preventing or treating central nervous system disease related to melatonin receptor, and an application in preparing medicines for preventing or treating depression.

The invention provides application of magnolo-4-O-beta-D-glucopyranoside (1) shown as the structural formula (I) or medicinal salts and pharmaceutical compositions thereof to preparing melatonin receptor agonists as well as preparing drugs for treating or preventing central nervous system diseases correlated with melatonin receptors. The magnolo-4-O-beta-D-glucopyranoside (1) is prepared through achemical synthesis method.

The invention provides four isoechinulin dimers (-)-uncarilins A(1a), (+)-uncarilins A(1b), (-)-uncarilin B(2a) and (+)-uncarilins B(2b) as shown in a structural formula (I), a pharmaceutical composition formed by a therapeutically effective amount of compound 1a/1b or 2a/2b and a pharmaceutically acceptable carrier or excipient, a preparation method of the compound 1a/1b or 2a/2b and the pharmaceutical composition thereof, a melatonin receptor agonist and an application of the isoechinulin dimmers in treatment or improvement of central nervous system diseases related to a melatonin receptor.

The invention belongs to the technical field of drugs and provides magnolol derivatives (1-7) as shown in a structural formula (I) or a pharmaceutical composition and application of the magnolol derivatives or the pharmaceutical composition in preparing a melatonin receptor agonist as well as application thereof in preparing drugs for treating or preventing melatonin receptor related central nervous system diseases.

The invention discloses application of a Toll-link receptor-3 (TLR3) agonist to preparation of medicines for promoting wound healing. The TLR3 agonist can promote the wound healing, can be used as an active component of the medicine (especially poluriboinosinic poluribocytidylic acid) for promoting the wound healing, can remarkably shorten the healing time of skin or mucosa wound, and has no pruritus, reddish hot pain or other adverse effects, and no obvious scar or skin tissue change, and high healing quality. The poluriboinosinic poluribocytidylic acid is hopeful to be a conventional medicine for normal individual, individual with difficulty in wound healing or wound healing of plastic and cosmetic surgery.

The invention provides a polybenzyl derivative (1-12) shown as a structural formula (I) or a drug composition of the polybenzyl derivative (1-12), a preparation method of the drug composition, and application of the drug composition to preparation of a melatonin receptor agonist and preparation of drugs for treating or preventing central nervous system diseases related to melatonin receptors.

The invention relates to a melatonin (MT1/MT2) receptor stimulant, and a preparation method and an application thereof. Specifically, the invention provides a novel melatonin (MT1/MT2) receptor stimulant and a preparation method thereof, and an application of the novel melatonin (MT1/MT2) receptor stimulant in preparation of medicines used for treating diseases or symptoms related to melatonin (MT1/MT2) receptors. The melatonin (MT1/MT2) receptor stimulant provided by the invention has good biological activity.

The present invention relates to the use of 5-HT1 agonists in pharmaceutical compositions, compounds and methods for treatment of movement disorders related to neurological dysfunctions. The invention is particularly relevant for treatment of patients suffering from tardive dyskinesia, Parkinson's disease and associated disorders thereof. Kits of parts comprising the 5-HT1 agonist compounds or pharmaceutical compositions according to the present invention, as well as methods of preparation are also provided by the present invention.